Sixfold increase in NICE's lung cancer treatment recommendations over the past decade. NICE has recommended osimertinib for ...

Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...

NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

For information the company have advised that they will no longer be making a submission, or making this gene therapy available in the UK. Therefore, in collaboration with the company, NICE has ...

The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps ...

Vamorolone (Agamree) is available on the NHS as a possible treatment for Duchenne muscular dystrophy (DMD) in people 4 years and over. Is this treatment right for me? Your healthcare professionals ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

There is a simple discount patient access scheme for vamorolone. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Vamorolone is recommended, within its marketing authorisation, as an option for treating Duchenne muscular dystrophy (DMD) in people 4 years and over. Vamorolone is only recommended if the company ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...